Pilot Study for Cyproheptadine in Hospitalized Patient for COVID-19

Inclusion Criteria: * Women and men aged 18 and over. * Requiring treatment for COVID 19 and whose clinical status corresponds to a score equal to or greater than 5 on the WHO Clinical Progression Scale. * For the prospective study, able to give informed consent. * Not presenting an exclusion criterion Exclusion Criteria: * Pregnancy * Patients with pre-existing terminal condition with life expectancy \< 6 months * Patient with clinically frailty according to a score of the clinical frailty scale equal or superior to 7 * Patients with pre-existing severe lung disease requiring home oxygen therapy. * Patients with pre-existing severe hepatic cirrhosis (Grade C according to the Child-Pugh classification) * Patients with pre-existing kidney failure (GFR strictly less than 15ml/min/1.73m2 according The KDIGO classification) or requiring renal replacement therapy. * Patients with pre-existing angle-closure glaucoma * Patient with symptomatic prostatic hypertrophy or bladder neck obstruction * Patient with history of seizure disorder * Patient with history of adverse reaction to antihistamines or to Cyproheptadine * Patients taking routinely SSRI or monoamine oxidase inhibitor therapy. * Patients presenting severe hepatic cytolysis with ALP \>5 ULN at the time of study inclusion.